DEERFIELD (dpa-AFX) - CTI BioPharma Corp. (CTIC) and Baxter International's BioScience business (BAX) announced new patient-reported outcome, or PRO, data for pacritinib - an investigational oral multikinase inhibitor with specificity for JAK2 and FLT3 - from the Phase 3 PERSIST-1 study. The company said the results show a significant reduction in the Total Symptom Score, and in each individual common disease-related symptom, from baseline to Week 24, in patients treated with pacritinib compared to best available therapy.
PERSIST-1 is a randomized, controlled Phase 3 registration-directed trial comparing the efficacy and safety of pacritinib to best available therapy in 327 patients with myelofibrosis. The company previously announced that the PERSIST-1 trial met its primary endpoint of spleen volume reduction of 35 percent or greater from baseline to Week 24 as measured by MRI/CT scan.
James Bianco, President and CEO of CTI BioPharma, said: 'These new data from the PERSIST-1 study further support our belief, not only in the activity of pacritinib, but also the potential to positively impact patients' daily lives by relieving the symptoms that accompany myelofibrosis.'
Copyright RTT News/dpa-AFX